Ark Biotech

Ark Biotech is a private, early-revenue stage company providing a no-code, AI-enhanced software platform for in silico bioprocess simulation. Founded in 2019, its core technology leverages dynamic models of cell culture physics, chemistry, and biology to help scientists run virtual experiments, optimize critical parameters, and de-risk scale-up. The platform is positioned as a decision-support tool for biopharma and CDMOs, aiming to significantly reduce development timelines and costs while improving manufacturing robustness and yield.

High-fidelity, multiphysics virtual bioreactor simulation software for upstream bioprocess development and optimization. Integrates models of cell culture biology, chemistry, and physics with a no-code interface and AI-assisted insights.

Ark operates in the digital bioprocess development and manufacturing software segment. Competitors range from large life science tool providers (e.g., Sartorius with its SIMCA models, Thermo Fisher) to specialized software startups and consulting firms offering modeling services. Differentiation hinges on predictive accuracy, ease of use, and integration into existing workflows.